AVEXIS, INC. (AVXS) financial statements (2021 and earlier)

Company profile

Business Address 2275 HALF DAY ROAD
BANNOCKBURN, IL 60015
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

3/31/2018
Q1
12/31/2017
Q4
9/30/2017
Q3
6/30/2017
Q2
3/31/2017
Q1
12/31/2016
Q4
9/30/2016
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments587324374418204240264
Cash and cash equivalents587324374418204240264
Other undisclosed current assets12899754
Total current assets:598332383427212245267
Noncurrent Assets
Property, plant and equipment63564640342417
Other noncurrent assets3322211
Other undisclosed noncurrent assets3      
Total noncurrent assets:69594943362517
TOTAL ASSETS:667392432469247271285
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities44562525202013
Accounts payable1411961234
Accrued liabilities3045151991710
Other undisclosed current liabilities29333544
Total current liabilities:73582727252418
Noncurrent Liabilities
Liabilities, other than long-term debt    1  
Other liabilities    1  
Other undisclosed noncurrent liabilities25111   
Total noncurrent liabilities:251111  
Total liabilities:98592828262418
Stockholders' equity
Stockholders' equity attributable to parent569333404441222246267
Common stock0000000
Additional paid in capital1,151692682671393388383
Accumulated deficit(582)(360)(278)(229)(171)(142)(116)
Total stockholders' equity:569333404441222246267
TOTAL LIABILITIES AND EQUITY:667392432469247271285

Income statement (P&L) ($ in millions)

3/31/2018
Q1
12/31/2017
Q4
9/30/2017
Q3
6/30/2017
Q2
3/31/2017
Q1
12/31/2016
Q4
9/30/2016
Q3
Operating expenses(222)(83)(50)(58)(30)(26)(21)
Operating loss:(222)(83)(50)(58)(30)(26)(21)
Loss from continuing operations before equity method investments, income taxes:(222)(83)(50)(58)(30)(26)(21)
Other undisclosed income from continuing operations before income taxes 2   0 
Net loss:(222)(80)(50)(58)(30)(25)(21)
Other undisclosed net income (loss) attributable to parent0(1)100(0)0
Net loss available to common stockholders, diluted:(222)(82)(49)(58)(30)(25)(21)

Comprehensive Income ($ in millions)

3/31/2018
Q1
12/31/2017
Q4
9/30/2017
Q3
6/30/2017
Q2
3/31/2017
Q1
12/31/2016
Q4
9/30/2016
Q3
Net loss:(222)(80)(50)(58)(30)(25)(21)
Comprehensive loss:(222)(80)(50)(58)(30)(25)(21)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent (1)100(0)0
Comprehensive loss, net of tax, attributable to parent:(222)(82)(49)(58)(30)(25)(21)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: